EA202091057A3 - Способы и композиции для лечения нарушений, ассоциированных со старением - Google Patents
Способы и композиции для лечения нарушений, ассоциированных со старениемInfo
- Publication number
- EA202091057A3 EA202091057A3 EA202091057A EA202091057A EA202091057A3 EA 202091057 A3 EA202091057 A3 EA 202091057A3 EA 202091057 A EA202091057 A EA 202091057A EA 202091057 A EA202091057 A EA 202091057A EA 202091057 A3 EA202091057 A3 EA 202091057A3
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- aging
- methods
- compositions
- treatment
- disorders associated
- Prior art date
Links
- 230000032683 aging Effects 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 241000124008 Mammalia Species 0.000 abstract 3
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3621—Extra-corporeal blood circuits
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D11/00—Solvent extraction
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/07—Proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Anesthesiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Mycology (AREA)
Abstract
Предлагаются способы лечения взрослого млекопитающего от нарушения, ассоциированного со старением. Аспекты способов включают в себя снижение уровня 2-микроглобулина (B2M) у млекопитающего в степени, достаточной для лечения млекопитающего от нарушения, ассоциированного со старением. Ряд нарушений, ассоциированных со старением, можно лечить посредством практического осуществления способов, причем данные нарушения включают в себя когнитивные нарушения.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562163222P | 2015-05-18 | 2015-05-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
EA202091057A2 EA202091057A2 (ru) | 2020-12-30 |
EA202091057A3 true EA202091057A3 (ru) | 2021-03-31 |
Family
ID=57320543
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201792437A EA035799B1 (ru) | 2015-05-18 | 2016-05-17 | Способ лечения взрослого млекопитающего от когнитивного нарушения, ассоциированного со старением |
EA202091057A EA202091057A3 (ru) | 2015-05-18 | 2016-05-17 | Способы и композиции для лечения нарушений, ассоциированных со старением |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201792437A EA035799B1 (ru) | 2015-05-18 | 2016-05-17 | Способ лечения взрослого млекопитающего от когнитивного нарушения, ассоциированного со старением |
Country Status (11)
Country | Link |
---|---|
EP (2) | EP3297702A4 (ru) |
JP (2) | JP7134089B2 (ru) |
KR (1) | KR20180030965A (ru) |
CN (2) | CN116687969A (ru) |
AU (4) | AU2016265948B2 (ru) |
CA (1) | CA2984645C (ru) |
EA (2) | EA035799B1 (ru) |
HK (1) | HK1248153A1 (ru) |
IL (1) | IL255319B2 (ru) |
NZ (1) | NZ738184A (ru) |
WO (1) | WO2016187217A2 (ru) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10626399B2 (en) | 2010-01-28 | 2020-04-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3) |
US20160208011A1 (en) | 2010-01-28 | 2016-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
US10487148B2 (en) | 2010-01-28 | 2019-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating aging-associated impairments |
US9161968B2 (en) | 2011-04-08 | 2015-10-20 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists |
US10905779B2 (en) | 2013-12-09 | 2021-02-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for screening human blood products comprising plasma using immunocompromised rodent models |
EP3079708A4 (en) | 2013-12-09 | 2017-08-30 | The Board of Trustees of the Leland Stanford Junior University | Methods and compositions for treating aging-associated conditions |
KR20240025721A (ko) | 2015-06-15 | 2024-02-27 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 노화와 연관된 질환을 치료하기 위한 방법 및 조성물 |
ES2830447T3 (es) * | 2015-12-15 | 2021-06-03 | Univ Leland Stanford Junior | Método para la prevención y/o el tratamiento del deterioro cognitivo asociado al envejecimiento y la neuroinflamación |
EP4353320A3 (en) | 2016-04-28 | 2024-05-15 | Alkahest, Inc. | Blood plasma and plasma fractions as therapy for tumor growth and progression |
EA039316B1 (ru) | 2016-10-24 | 2022-01-12 | Алкахест, Инк. | Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением |
US11040068B2 (en) | 2017-04-26 | 2021-06-22 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
MA48480A (fr) | 2017-04-26 | 2020-03-04 | Alkahest Inc | Schéma posologique pour le traitement de déficiences cognitives et motrices avec du plasma sanguin et des produits de plasma sanguin |
EP3870190A4 (en) | 2018-10-26 | 2022-09-07 | Alkahest, Inc. | USE OF PLASMA AND PLASMA FRACTIONS TO REDUCE PAIN, IMPROVE WOUND HEALING AND POST-OPERATIVE RECOVERY |
CN113081079B (zh) * | 2021-03-30 | 2022-04-22 | 中国科学院生态环境研究中心 | 血桥限位器 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0236509B1 (en) * | 1985-09-19 | 1993-02-10 | Toray Industries, Inc. | B2-microglobulin-removing column |
DE3887114D1 (de) | 1987-12-11 | 1994-02-24 | Akzo Nv | Biocompatible Dialysemembran aus Cellulose mit erhöhter Beta-2-Microglobulinadsorption. |
FR2646607B1 (fr) | 1989-05-03 | 1991-08-30 | Inst Nat Sante Rech Med | Anticorps monoclonaux anti-b2 microglobuline |
US5614396A (en) | 1990-06-14 | 1997-03-25 | Baylor College Of Medicine | Methods for the genetic modification of endogenous genes in animal cells by homologous recombination |
ATE352612T1 (de) | 1990-08-29 | 2007-02-15 | Pharming Intellectual Pty Bv | Homologe rekombination in säugetier-zellen |
FR2685346B1 (fr) | 1991-12-18 | 1994-02-11 | Cis Bio International | Procede de preparation d'arn double-brin, et ses applications. |
US5240614A (en) | 1992-01-10 | 1993-08-31 | Baxter International Inc. | Process for removing unwanted materials from fluids and for producing biological products |
WO1995006764A2 (en) | 1993-09-03 | 1995-03-09 | Vpi Holdings Ltd. | Oligonucleotides with rna cleavage activity |
AU706417B2 (en) | 1994-02-23 | 1998-06-17 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for inhibiting the expression of disease related genes |
FR2722411B1 (fr) | 1994-07-18 | 1996-10-04 | Union Pharma Scient Appl | Immunonanoparticules revetues d'anticorps monoclonaux anti-beta2 microglobuline et leur utilisation pour la prophylaxie et/ou le traitement de pathologies dues a une infection par le virus hiv |
US5780296A (en) | 1995-01-17 | 1998-07-14 | Thomas Jefferson University | Compositions and methods to promote homologous recombination in eukaryotic cells and organisms |
JPH11503914A (ja) | 1995-04-21 | 1999-04-06 | セル ジェネシス,インコーポレイテッド | 大ゲノムdna欠失の生成 |
US5776744A (en) | 1995-06-07 | 1998-07-07 | Yale University | Methods and compositions for effecting homologous recombination |
US5925544A (en) | 1996-11-18 | 1999-07-20 | Novo Nordisk A/S | Method of homologous recombination followed by in vivo selection of DNA amplification |
US5830698A (en) | 1997-03-14 | 1998-11-03 | Idec Pharmaceuticals Corporation | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same |
US5948653A (en) | 1997-03-21 | 1999-09-07 | Pati; Sushma | Sequence alterations using homologous recombination |
US20020159995A1 (en) | 1997-07-30 | 2002-10-31 | Renal Tech International | Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood, generated as a result of extracorporeal blood processing |
US5904663A (en) | 1997-07-30 | 1999-05-18 | Braverman; Andrew | Method of removing beta-2 microglobulin from blood |
US6416487B1 (en) * | 1997-07-30 | 2002-07-09 | Renal Tech International Llc | Method of removing beta-2 microglobulin from blood |
US7066900B2 (en) | 1998-12-23 | 2006-06-27 | Life Therapeutics | Removal of metabolic components from blood |
AUPR748501A0 (en) | 2001-09-04 | 2001-09-27 | Life Therapeutics Limited | Renal dialysis |
AUPP790898A0 (en) | 1998-12-23 | 1999-01-28 | Life Therapeutics Limited | Renal dialysis |
DE69942282D1 (de) | 1999-01-22 | 2010-06-02 | Dow Global Technologies Inc | Oberflächenverändertes divinylbenzenharz mit hämokompatibler beschichtung |
EP1272630A2 (en) | 2000-03-16 | 2003-01-08 | Genetica, Inc. | Methods and compositions for rna interference |
US7553484B2 (en) | 2001-06-05 | 2009-06-30 | The Regents Of The University Of California | Modulating neuronal outgrowth via the major histocompatibility complex class I (MHC I) molecule |
US20030153519A1 (en) | 2001-07-23 | 2003-08-14 | Kay Mark A. | Methods and compositions for RNAi mediated inhibition of gene expression in mammals |
US20030180811A1 (en) | 2002-03-11 | 2003-09-25 | Montero-Julian Felix A. | Immunoassays for beta2-microglobulin |
AU2003221886A1 (en) | 2002-04-12 | 2003-10-27 | The Board Of Trustees Of The University Of Arkansas | Beta2-MICROGLOBILIN (Beta2m) AND ANTI-Beta2m BINDING AGENTS AS ANTI-CANCER THERAPEUTICS |
US7037276B2 (en) | 2002-07-02 | 2006-05-02 | Precision Medical Devices, Inc. | Biopsy device |
US20040127445A1 (en) * | 2002-08-28 | 2004-07-01 | Chondrogene Limited | Beta-2 microglobulin (B2M) and B2M related gene products for the regulation of osteoarthritis pathogenesis and chondrocyte proliferation |
EP1563069B1 (en) | 2002-11-22 | 2012-06-06 | Institut Clayton De La Recherche | Compositions and systems for the regulation of genes |
GB0307206D0 (en) | 2003-03-28 | 2003-04-30 | Axordia Ltd | Hyperproliferation |
WO2006130949A1 (en) | 2005-06-08 | 2006-12-14 | Replicor Inc. | Anti amyloid-related disease molecules and their uses |
US8211310B2 (en) | 2006-11-20 | 2012-07-03 | Cytosorbents, Inc. | Size-selective polymer system |
EP2216060B2 (en) * | 2007-12-06 | 2021-03-17 | Asahi Kasei Medical Co., Ltd. | Porous hollow fiber membrane for blood treatment |
WO2010017443A2 (en) | 2008-08-07 | 2010-02-11 | Da Zen Group, Llc | Anti-beta-2-microglobulin agents and the use thereof |
CA2739076A1 (en) | 2008-10-02 | 2010-04-08 | Celtaxsys, Inc. | Methods of modulating the negative chemotaxis of immune cells |
US8754034B2 (en) | 2009-02-06 | 2014-06-17 | The Regents Of The University Of California | Structure-based design of peptide inhibitors of amyloid fibrillation |
US20130040844A1 (en) | 2010-01-28 | 2013-02-14 | The Board Of Trustees Of The Leland Stanford Junior University | Biomarkers of aging for detection and treatment of disorders |
US20130331327A1 (en) | 2012-06-08 | 2013-12-12 | Vittorio Bellotti | Variant Beta2-microglobulin, characterization of the same and applications thereof |
EP2781523A1 (en) * | 2013-03-18 | 2014-09-24 | Miltenyi Biotec GmbH | Lipophilic oligonucleotide analogs |
EP3074525A4 (en) * | 2013-11-26 | 2017-08-23 | University of North Texas Health Science Center at Fort Worth | Personalized medicine approach for treating cognitive loss |
-
2016
- 2016-05-17 KR KR1020177035957A patent/KR20180030965A/ko not_active Application Discontinuation
- 2016-05-17 CN CN202310374205.5A patent/CN116687969A/zh active Pending
- 2016-05-17 AU AU2016265948A patent/AU2016265948B2/en active Active
- 2016-05-17 EP EP16797159.7A patent/EP3297702A4/en not_active Withdrawn
- 2016-05-17 NZ NZ73818416A patent/NZ738184A/en unknown
- 2016-05-17 EA EA201792437A patent/EA035799B1/ru unknown
- 2016-05-17 CA CA2984645A patent/CA2984645C/en active Active
- 2016-05-17 CN CN201680028881.5A patent/CN107921188A/zh active Pending
- 2016-05-17 WO PCT/US2016/032907 patent/WO2016187217A2/en active Application Filing
- 2016-05-17 EP EP21162695.7A patent/EP3892315A1/en active Pending
- 2016-05-17 JP JP2018512817A patent/JP7134089B2/ja active Active
- 2016-05-17 EA EA202091057A patent/EA202091057A3/ru unknown
-
2017
- 2017-10-30 IL IL255319A patent/IL255319B2/en unknown
-
2018
- 2018-06-15 HK HK18107779.2A patent/HK1248153A1/zh unknown
-
2019
- 2019-02-26 AU AU2019201337A patent/AU2019201337B9/en active Active
-
2020
- 2020-07-28 AU AU2020210181A patent/AU2020210181B2/en active Active
-
2021
- 2021-01-29 JP JP2021013639A patent/JP7323561B2/ja active Active
-
2022
- 2022-08-25 AU AU2022221494A patent/AU2022221494A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN107921188A (zh) | 2018-04-17 |
AU2020210181B2 (en) | 2022-05-26 |
JP2018518530A (ja) | 2018-07-12 |
JP7134089B2 (ja) | 2022-09-09 |
WO2016187217A2 (en) | 2016-11-24 |
EP3297702A2 (en) | 2018-03-28 |
EA035799B1 (ru) | 2020-08-12 |
NZ738184A (en) | 2019-09-27 |
WO2016187217A3 (en) | 2017-01-05 |
AU2022221494A1 (en) | 2022-09-29 |
IL255319B2 (en) | 2023-03-01 |
CA2984645A1 (en) | 2016-11-24 |
AU2016265948B2 (en) | 2018-12-06 |
EP3297702A4 (en) | 2019-01-16 |
EP3892315A1 (en) | 2021-10-13 |
IL255319B (en) | 2022-11-01 |
EA202091057A2 (ru) | 2020-12-30 |
IL255319A0 (en) | 2017-12-31 |
AU2016265948A1 (en) | 2018-01-04 |
AU2019201337B2 (en) | 2020-05-14 |
EA201792437A1 (ru) | 2018-04-30 |
JP7323561B2 (ja) | 2023-08-08 |
KR20180030965A (ko) | 2018-03-27 |
HK1248153A1 (zh) | 2018-10-12 |
JP2021073264A (ja) | 2021-05-13 |
CN116687969A (zh) | 2023-09-05 |
AU2019201337B9 (en) | 2020-05-21 |
CA2984645C (en) | 2023-01-10 |
AU2020210181A1 (en) | 2020-08-13 |
AU2019201337A1 (en) | 2019-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202091057A2 (ru) | Способы и композиции для лечения нарушений, ассоциированных со старением | |
EA201890020A1 (ru) | Способы и композиции для лечения ассоциированных со старением состояний | |
MX2021014709A (es) | Composiciones para usarse en el incremento de los niveles de globulos rojos y el tratamiento de enfermedad de celulas falciformes. | |
MX2019003623A (es) | Composiciones y metodos para el tratamiento de afecciones oftalmicas. | |
PL3297644T3 (pl) | Metody terapii zaburzeń ze spektrum autyzmu i powiązanych objawów | |
EA201790737A1 (ru) | Комбинированная терапия | |
MX2023006304A (es) | Administracion de celulas t dise?adas para tratamiento de canceres en el sistema nervioso central. | |
HK1258448A1 (zh) | 診斷和治療行為障礙的方法 | |
EA201990296A1 (ru) | Антитела против siglec-7 для лечения рака | |
EA201992251A1 (ru) | Противораковые вакцины и способы лечения с их применением | |
ZA202101797B (en) | Hair treatment compositions, methods, and kits for treating hair | |
BR112018001853A2 (pt) | métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio | |
MX2018013663A (es) | Metodos para tratar trastornos de sueño de ritmo circadiano. | |
IL269082A (en) | Methods for treating lysosomal disorders | |
BR112019001039A2 (pt) | composição para uso no tratamento de transtorno depressivo maior | |
MX2018012902A (es) | Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal. | |
IL267229A (en) | Methods of treating ocular disorders | |
EA201991650A1 (ru) | Способы лечения неврологических расстройств | |
BR112018007566A2 (pt) | neuromodulação periférica dependente do estado para tratar disfunção da bexiga | |
EA201892297A1 (ru) | Способы лечения холестатических и фибротических заболеваний | |
SG11202006618PA (en) | Compositions and methods for treating retinal disorders | |
IL281729A (en) | Low-intensity therapy with CPX-351 for hematologic disorders | |
MX2017010654A (es) | Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres. | |
MX2019004804A (es) | Tratamiento para el prurigo nodula. | |
EA201990930A1 (ru) | Способы, композиции и режимы дозирования для лечения или профилактики связанных с интерфероном-гамма заболеваний |